Throughout the month of July, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from a busy last few weeks at both the 2023 EASL Congress in Vienna and the American Diabetes Association’s 83rd Scientific Sessions meeting in San Diego.
This first installment comprises two distinct 1:1 interviews with Tsunami co-host Roger Green, one with key opinion leader Mazen Noureddin and the other with co-host Jörn Schattenberg.
This final conversation between Roger and Jörn begins by moving beyond the subject of drugs to the importance behind noninvasive testing and the myriad ways by which the term artificial intelligence is being claimed. Jörn talks about a poster he shared at EASL around an AI-assisted mode called qVessel which investigates the ability of researchers to quantitate changes in blood vessels and liver architecture as fibrosis progresses. This example provides contrast between how we develop diagnostic scientific insight versus drug approval process versus clinical applications and patient treatment. The conversation continues on to highlight some of what Jörn and Roger consider to be some of the most exciting drug development pieces to emerge from the EASL and ADA meetings. This leads to comments around how the nature of the questions being asking in 2023 versus 2019 demonstrates how much the field has learned about liver disease over the last few years. Our entire key opinion leader and advocate team has been struck forcibly by how many studies in the last month provided significant advances in knowledge and how some of these advances may change an underlying appreciation of drugs, diagnostics, artificial intelligence, machine learning and how we think about Fatty Liver disease overall.
Both conversations with Mazen and Jörn explore different perspectives around the complexities associated with drug development and the wider field’s understanding of Steatotic Liver Disease (SLD). Stay tuned for more in the subsequent conversations to be released. If you have any questions or comments around these meetings, the discussed therapeutics or the new nomenclature, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!